FAQ

PD 173955

Known as: PD-173955, PD173955 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
012319992017

Related topics

Related topics

2 relations

Broader (2)

PyridonesPyrimidines

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
PD 173955
Pyrimidines
Pyridones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.
The receptor tyrosine kinase EPHA2 has gained attention as a therapeutic drug target for cancer and infectious diseases. However… (More)
Is this relevant?
2010
2010
New effective inhibitors of the Abelson kinase.
The effects of substituents on the aryl ring were studied by the preparation and testing of several PD173955 analogs. Inserting a… (More)
Is this relevant?
2008
2008
Induced disorder in protein-ligand complexes as a drug-design strategy.
Protein associations are poorly understood from a chemical perspective. If the contrary were true, drug inhibitors would be… (More)
Is this relevant?
2006
2006
MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells.
Organic small molecules generally act by perturbing the function of one or more cellular target proteins, the identification of… (More)
Is this relevant?
2006
2006
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Anaplastic lymphoma kinase (ALK) is a valid target for anticancer therapy; however, potent ALK inhibitors suitable for clinical… (More)
Is this relevant?
2006
2006
Phosphorylation of IkappaB-beta is necessary for neuronal survival.
Cerebellar granule neurons undergo apoptosis when switched from culture medium containing depolarizing levels of potassium (high… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl. Imatinib mesylate (also known as… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
2002
2002
c-Kit Receptor Tyrosine Kinases Characterization of Potent Inhibitors of the Bcr-Abl and the Updated Version
The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl. Imatinib mesylate (also known as… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
1999
1999
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
src kinase activity is elevated in some human tumors, including breast and colon cancers. The precise cellular function of the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?